LENZ Therapeutics reports Q1 net loss $16.6M; positive Phase 3 presbyopia data, NDA on track mid-2024

LENZ Therapeutics, Inc.

2024-Q1 EPS reported -$3.53

Net loss $16.6M ($3.53/share) vs $12.7M ($6.50/share) in Q1 2023; cash $213.3M.
Phase 3 CLARITY study for LNZ100 met all primary/secondary endpoints; 84% achieved ≥4 lines near vision improvement.
NDA submission to FDA for LNZ100 planned for mid-2024; commercial launch as early as H2 2025.
Completed merger with Graphite Bio and concurrent $53.5M private placement in March 2024.
Jeff George appointed Chairman; Dan Chevallard CFO; commercial buildout underway including third-party logistics.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

LENZ Therapeutics, Inc. reported financial results for the quarter ended March 31, 2024.

Period: the quarter ended March 31, 2024
Result: reported results

Exact text from the filing

On May 8, 2024, LENZ Therapeutics, Inc. issued a press release announcing its financial results for the quarter ended March 31, 2024.

View on SEC.gov

708 earnings releases filed in the last 30 days. Browse all earnings releases →

LENZ Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001815776-24-000039

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.